Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JD.Com Inc (JD) vs Mesoblast Limited (MESO) Price & Performance

JD.Com IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

JD.Com Inc vs Mesoblast Limited — how do they compare? JD.Com Inc trades at $31.25 (market cap $45.40B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: JD.Com Inc is far larger — about 21× Mesoblast Limited's market cap, and JD.Com Inc pays a 2.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

JDMESO
Market Cap
$45.40B$2.16B
Sector
Consumer CyclicalTechnology
52-Week High
$36.17$20.96
52-Week Low
$25.19$12.88
Enterprise Value
$31.45B$2.17B
Dividend Yield
2.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JD.Com Inc

JD.com trades at $32.97, up 0.49% with bullish technical signals and strong institutional support. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.74 beating expectations by 30%. Revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analysts maintain a strong buy consensus with $39.50 price target, representing 20% upside potential.

JD offers compelling value with attractive valuation multiples (P/S 0.25, P/E 24.03) and robust cash flow generation. Key risks include regulatory scrutiny of the Ceconomy acquisition and margin pressure from competitive e-commerce markets. The upcoming Q2 2026 earnings on August 13, 2026 will be critical for confirming growth trajectory.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO